TreatmentTrends: Renal Cell Carcinoma 2015 (US) is part of a series of reports that examine current trends in the management of localized to advanced/metastatic renal cell carcinoma (RCC) from the perspective of medical oncologists. TreatmentTrends® are syndicated reports that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. These reports evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  • Assess current and anticipated prescribing of old and new agents for patients with advanced/metastatic RCC. How does prescribing of currently available therapies differ by line of therapy? How is prescribing anticipated to change over the next six months?

  • Assess the importance and performance of various attributes (e.g., efficacy, safety, administration) of agents used to treat advanced/metastatic RCC. For example, which therapies, if any, have a minimal impact on the quality of life of patients with advanced/metastatic RCC, according to surveyed physicians? How do currently marketed products, such as Pfizer’s Sutent (sunitinib) and Inlyta (axitinib), Bayer HealthCare/Onyx Pharmaceuticals’ Nexavar (sorafenib), and GlaxoSmithKline’s Votrient (pazopanib), perform in terms of safety and tolerability, delaying time to disease progression, and improving overall survival in advanced/metastatic RCC patients?

  • Assess sales representatives’ contact frequency, and physician message recall between products. When was the last time a sales representative visited medical oncologists for the various current therapies? What percentages of physicians were visited in the past month, and what messages were recalled by brand?

  • Understand medical oncologists’ perception of late-phase RCC therapies, including awareness of and familiarity with emerging agents. This report covers approximately 14 products in late-stage development. Which drug characteristics do surveyed physicians perceive to be the most important for advanced/metastatic RCC therapies? How do surveyed medical oncologists rank future RCC treatments?

Scope:

Markets covered: United States.

Primary research: 99 medical oncologists.

Indication coverage: Renal cell carcinoma.

Author(s): Kirsha Naicker, Ph.D., M.Sc., B.Sc.

Related Reports

Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma | Disease Landscape and Forecast | G7 | DLSFON0009-2020

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma - Epidemiology - Emerging Markets

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of...

View Details

Renal Cell Carcinoma - Epidemiology - Europe

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 count...

View Details